Evidence map›Paper›PMID 36791574›Full record

ArticlePediatric neurology2023

The Spectrum of MORC2-Related Disorders: A Potential Link to Cockayne Syndrome.

Seth A Stafki, Johnnie Turner, Hannah R Littel, Christine C Bruels, Don Truong, Ursula Knirsch, Georg M Stettner, Urs Graf, Wolfgang Berger, Maria Kinali and 14 more

Open access · greenAbstract read
In one paragraph

Article in Pediatric neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Dystonia: Insights into Mechanisms and Novel Therapeutics.Current neurology and neuroscience reports · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Clinical and genetic analysis ofFrontiers in genetics · 2025
    Article
  8. Article
  9. Spectrum ofGenes · 2024
    Article
  10. Article
  11. A Novel HeterozygousCase reports in genetics · 2024
    Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 11 institutions in 6 countries.

Seth A StafkiDepartment of Neurology and Paul and Sheila Wellstone Muscular Dystrophy Center, University of Minnesota Medical School, Minneapolis, Minnesota.
Johnnie TurnerDepartment of Neurology and Paul and Sheila Wellstone Muscular Dystrophy Center, University of Minnesota Medical School, Minneapolis, Minnesota.
Hannah R LittelDepartment of Neurology and Paul and Sheila Wellstone Muscular Dystrophy Center, University of Minnesota Medical School, Minneapolis, Minnesota.
Christine C BruelsDepartment of Neurology and Paul and Sheila Wellstone Muscular Dystrophy Center, University of Minnesota Medical School, Minneapolis, Minnesota.
Don TruongDepartment of Neurology and Paul and Sheila Wellstone Muscular Dystrophy Center, University of Minnesota Medical School, Minneapolis, Minnesota.
Ursula KnirschNeuromuscular Center Zürich and Department of Pediatric Neurology, University Children's Hospital Zürich, University of Zürich, Zürich, Switzerland.
Georg M StettnerNeuromuscular Center Zürich and Department of Pediatric Neurology, University Children's Hospital Zürich, University of Zürich, Zürich, Switzerland.
Urs GrafInstitute of Medical Molecular Genetics (IMMG), University of Zürich, Zürich, Switzerland.
Wolfgang BergerInstitute of Medical Molecular Genetics (IMMG), University of Zürich, Zürich, Switzerland; Neuroscience Center Zurich (NCZ), University and ETH Zürich, Zürich, Switzerland; Zürich Center for Integrative Human Physiology (ZIHP), University of Zürich, Zürich, Switzerland.
Maria KinaliDepartment of Brain Sciences, Imperial College London and Portland Hospital HCA International, London, United Kingdom.
Heinz JungbluthEvelina Children's Hospital and King's College London, University of Manchester, London, United Kingdom.
Christina A PacakDepartment of Neurology and Paul and Sheila Wellstone Muscular Dystrophy Center, University of Minnesota Medical School, Minneapolis, Minnesota.
Jayne HughesAmy and Friends Cockayne Syndrome/Trichothiodystrophy Support, Wirral, United Kingdom.
Amytice MirchiDepartments of Neurology and Neurosurgery and Pediatrics, McGill University, Montreal, Canada; Child Health and Human Development Program, Research Institute of the McGill University Health Center, Montreal, Canada.
Alexa DerksenDepartments of Neurology and Neurosurgery and Pediatrics, McGill University, Montreal, Canada; Child Health and Human Development Program, Research Institute of the McGill University Health Center, Montreal, Canada.
Catherine Vincent-DelormeDepartment of Clinical Genetics, Hôpital Jeanne de Flandre, CHU Lille, Lille, France.
Arjan F TheilDepartment of Molecular Genetics, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Geneviève BernardDepartments of Neurology and Neurosurgery and Pediatrics, McGill University, Montreal, Canada; Child Health and Human Development Program, Research Institute of the McGill University Health Center, Montreal, Canada; Department of Human Genetics, McGill University, Montreal, Canada; Division of Medical Genetics, Department Specialized Medicine, McGill University Health Center, Montreal, Canada.
David EllisSouth East Genomics Laboratory Hub, Guy's Hospital, London, United Kingdom.
Hiva FassihiSt. John's Institute of Dermatology, Rare Disease Centre, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom.
Alan R LehmannGenome Damage and Stability Centre, University of Sussex, Brighton, United Kingdom.
Vincent LaugelService de Pédiatrie 1, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg, Strasbourg, France; Laboratoire de Génétique médicale, INSERM U1112, Institut de génétique médicale d'Alsace, Faculté de Médecine de Strasbourg, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
Shehla MohammedSouth East Thames Regional Genetics Service and Rare Diseases Centre Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
Peter B KangDepartment of Neurology and Paul and Sheila Wellstone Muscular Dystrophy Center, University of Minnesota Medical School, Minneapolis, Minnesota; Institute for Translational Neuroscience, University of Minnesota, Minneapolis, Minnesota. Electronic address: pkang@umn.edu.
University of Minnesota · USUniversity of Zurich · CHMcGill University Health Centre · CAGuy's and St Thomas' NHS Foundation Trust · GBCentre Hospitalier Universitaire de Lille · FRErasmus MC · NLGuy's Hospital · GBImperial College London · GBInserm · FRUniversity of London · GBUniversity of Sussex · GB

Funding

Optimized Production and Validation of Rationally Designed AAV Vectors for Cockayne Syndrome Gene TherapyR01FD007483 · FDA · UNIVERSITY OF MINNESOTA · PI ASLANIDI, GEORGE V, PACAK, CHRISTINA A. · 2021 to 2023
$1.8M
FDA HHS R01 FD007483
6 · The paper itself

Abstract

backgroundCockayne syndrome (CS) is a DNA repair disorder primarily associated with pathogenic variants in ERCC6 and ERCC8. As in other Mendelian disorders, there are a number of genetically unsolved CS cases.

methodsWe ascertained five individuals with monoallelic pathogenic variants in MORC2, previously associated with three dominantly inherited phenotypes: an axonal form of Charcot-Marie-Tooth disease type 2Z; a syndrome of developmental delay, impaired growth, dysmorphic facies, and axonal neuropathy; and a rare form of spinal muscular atrophy.

resultsOne of these individuals bore a strong phenotypic resemblance to CS. We then identified monoallelic pathogenic MORC2 variants in three of five genetically unsolved individuals with a clinical diagnosis of CS. In total, we identified eight individuals with MORC2-related disorder, four of whom had clinical features strongly suggestive of CS.

conclusionsOur findings indicate that some forms of MORC2-related disorder have phenotypic similarities to CS, including features of accelerated aging. Unlike classic DNA repair disorders, MORC2-related disorder does not appear to be associated with a defect in transcription-coupled nucleotide excision repair and follows a dominant pattern of inheritance with variants typically arising de novo. Such de novo pathogenic variants present particular challenges with regard to both initial gene discovery and diagnostic evaluations. MORC2 should be included in diagnostic genetic test panels targeting the evaluation of microcephaly and/or suspected DNA repair disorders. Future studies of MORC2 and its protein product, coupled with further phenotypic characterization, will help to optimize the diagnosis, understanding, and therapy of the associated disorders.

Indexed as

Cockayne SyndromeMicrocephalyDNA Repair EnzymesHumansMutationPhenotypeTranscription FactorsDNA Repair EnzymesERCC8 protein, humanMORC2 protein, humanTranscription FactorsCockayne syndromeDNA repairMicrocephalyMORC2

Identifiers

PMID36791574
PMCPMC10098370
OpenAlexW4319993262

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.